Saudi MoH Protocol for Patients Suspected of/Confirmed with COVID-19

Supportive care and antiviral treatment of suspected or confirmed COVID-19 infection

(Version 3.1) August 19th, 2021

Disclaimer: This is a living guidance that is subject to change as more evidence accumulates. It will be updated regularly and whenever needed. The guidance should be used to assist healthcare practitioners select the best available pharmacotherapy for COVID-19 infection according the best available and current evidence and is not intended to replace clinical judgement but rather to complement it. The evidence is inconclusive regarding the efficacy of most medications for covid-19. It is important to explain this to patient and family and obtain informed consent for use of these medications for unapproved indications. Convalescent plasma transfusion should only be used according to an approved study protocol.

<table>
<thead>
<tr>
<th>COVID-19 Testing*</th>
<th>Category</th>
<th>Supportive Care</th>
<th>Pharmacotherapy</th>
<th>Precautions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Suspicious Cases (follow case definition published in Saudi CDC guidelines)</td>
<td>Mild to Moderate: Symptoms with no shortness of breath</td>
<td>– Treat symptoms</td>
<td>– Not required</td>
<td>– Paracetamol (acetaminophen) is the preferred agent for pain/fever see below table “Medication Related Information”</td>
</tr>
<tr>
<td></td>
<td></td>
<td>– If no hospital admission required, need to follow instructions and recommendations published by Saudi CDC</td>
<td>– Do not stop ACEI/ARBs in patients with hypertension, post-MI, or heart failure</td>
<td>– Labs and work-up: CBC, Urea/Electrolytes, Creatinine, CRP, LFTs, Chest X-ray, COVID-19 PCR tests</td>
</tr>
<tr>
<td></td>
<td>Mild to Moderate: Symptoms with no shortness of breath in high-risk patients§</td>
<td>– Treat symptoms</td>
<td>– Case shall be discussed with infectious disease specialist, to initiate empirical antiviral therapy, while awaiting PCR result.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>– If hospital admission is not required, follow instructions and recommendations published by Saudi CDC</td>
<td>– Do not stop ACEI/ARBs in patients with hypertension, post-MI, heart failure</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mild to Moderate: Symptoms with shortness of breath in high-risk patients§</td>
<td>– Consult Infectious Disease Specialist</td>
<td></td>
<td>If decision is to treat empirically, follow the treatment option under confirmed by PCR</td>
</tr>
</tbody>
</table>

*COVID-19 Testing:
- Suspicious Cases (follow case definition published in Saudi CDC guidelines)
- Mild to Moderate: Symptoms with no shortness of breath
- Mild to Moderate: Symptoms with no shortness of breath in high-risk patients§
- Mild to Moderate: Symptoms with shortness of breath in high-risk patients§

§This table includes additional information and instructions for patients with COVID-19.
# Saudi MoH Protocol for Patients Suspected of/Confirmed with COVID-19

Supportive care and antiviral treatment of suspected or confirmed COVID-19 infection

(Version 3.1) August 19th, 2021

<table>
<thead>
<tr>
<th>COVID-19 Testing</th>
<th>Category</th>
<th>Supportive Care</th>
<th>Pharmacotherapy</th>
<th>Precautions</th>
</tr>
</thead>
<tbody>
<tr>
<td>PCR Confirmed Cases</td>
<td>Mild to Moderate: Symptoms (no O₂ requirements/no evidence of pneumonia but with other symptoms of covid-19 e.g., fever)</td>
<td>- Criteria for using Anti-SARS-CoV-2 Monoclonal Antibodies should only be used in patients with high risk for progression to severe COVID-19 and/or hospitalization. These include: 1. Aged ≥65 years 2. Obesity (BMI &gt;30) 3. Uncontrolled diabetes. 4. Cardiovascular disease (including congenital heart disease)</td>
<td>In case of new onset cough and fever or anosmia, or both) within 7 days  - Consider inhaled budesonide (Pulmicort®)  - Adult Dosing: 800 μg per actuation (two inhalations) twice a day until symptom resolution  - Consider starting any of the following according to clinical evaluation and treating consultant’s discretion:  - Consider Favipiravir  - Adult Dosing: 1800 mg/dose twice a day on the first day; followed by 800 mg/dose twice a day for 7-10 days  - Pediatric Dosing:  - 10-15 kg: Loading Dose: One tablet PO BID for One day (maximum 400 mg/day). Maintenance from Day 2: Half tablet (100 mg) PO BID (maximum 200 mg/day)  - 16-21 kg: Loading Dose: Two tablets PO BID One day (maximum 800 mg/day). Maintenance from Day2: One Tablet PO BID (maximum 400 mg/day)  - 22-35 kg: Loading Dose: Three Tablets PO BID for One day (maximum 1200 mg/day). Maintenance from Day2: One tablet PO BID (maximum 600 mg/day)  - 36-45 kg: Loading Dose: Four tablets PO BID for One day (maximum 1600mg/day). Maintenance from Day2: Two tablets PO BID (maximum 800 mg/day)  - 46-55 kg: Loading Dose: Five tablets PO BID for One day (maximum 2000 mg/day). Maintenance from Day2: Two Tablets qAM, Three Tablets qPM (maximum 1000 mg/day)  - For &gt;55 kg: Can use adult dosing if age ≥16 years, if age &lt;16years use dosing of 46-55 kg range</td>
<td>Inhaled budesonide (Pulmicort®) see below table “Medication Related Information” - Bronchospasm, oral candidiasis, and vasculitis Favipiravir (non-formulary and non-SFDA registered) see below table “Medication Related Information” - Contraindicated in pregnancy Anticoagulation see below “Thromboprophylaxis” Casirivimab plus imdevimab non-formulary and non-SFDA registered see below table “Medication Related Information” - May cause infusion-related reactions, hypersensitivity/anaphylaxis during infusion and for ≥1 hour following infusion completion Sotrovimab non-formulary and non-SFDA registered see below table “Medication Related Information”</td>
</tr>
</tbody>
</table>
# Saudi MoH Protocol for Patients Suspected of/Confirmed with COVID-19

Supportive care and antiviral treatment of suspected or confirmed COVID-19 infection

(Version 3.1) August 19th, 2021

<table>
<thead>
<tr>
<th>COVID-19 Testing</th>
<th>Category</th>
<th>Supportive Care</th>
<th>Pharmacotherapy</th>
<th>Precautions</th>
</tr>
</thead>
<tbody>
<tr>
<td>PCR Confirmed Cases</td>
<td>Moderate-to-severe Chronic lung diseases (e.g., chronic obstructive pulmonary disease, asthma, interstitial lung disease, cystic fibrosis, pulmonary hypertension)</td>
<td>- Treat symptoms&lt;br&gt;- Follow instructions and recommendations published by Saudi CDC <a href="https://covid19.cdc.gov.sa/professionals-health-workers/">https://covid19.cdc.gov.sa/professionals-health-workers/</a></td>
<td>For non-hospitalized ≤12 years of age patients at high risk of clinical progression treatment should start after positive PCR and within 10 days of symptom onset. (when available):&lt;br&gt;- Consider Casirivimab 600 mg plus imdevimab 600 mg IV infusion once for patient weight ≥40 kg. If IV infusions are not feasible or would cause a delay in treatment, casirivimab 600 mg plus imdevimab 600 mg administered by four subcutaneous injections (2.5 mL per injection) can be used as an alternative. OR&lt;br&gt;- Consider sorotrimerb for patient weight ≥40 kg: 500 mg intravenous IV infusion once.</td>
<td>- May cause infusion-related reactions, hypersensitivity/anaphylaxis during infusion and for ≥1 hour following infusion completion</td>
</tr>
<tr>
<td></td>
<td>Severe: Clinical signs of pneumonia (fever, cough, dyspnea, fast breathing) and one of the following:&lt;br&gt;- Respiratory rate &gt;30/min (adults); &gt;40/min (children &lt; 5 years)&lt;br&gt;- Blood oxygen saturation &lt;90% on room air&lt;br&gt;- Severe respiratory distress</td>
<td>- Antibiotics and antifungals according to local antibiogram and institutional pneumonia management guidelines/pathways.</td>
<td>Consider starting any of the following according to clinical evaluation and treating consultant’s discretion:&lt;br&gt;- Consider Favipiravir&lt;br&gt;  o Adult Dosing: 1800 mg/dose twice a day on the first day; followed by 800 mg/dose twice a day for 7-10 days.&lt;br&gt;  o Pediatric Dosing:&lt;br&gt;    - 10-15 kg: Loading Dose: One tablet PO BID for One day (maximum 400 mg/day). Maintenance from Day 2: Half tablet (100 mg) PO BID (maximum 200 mg/day)&lt;br&gt;    - 16-21 kg: Loading Dose: Two tablets PO BID One day (maximum 800 mg/day). Maintenance from Day2: One Tablet PO BID (maximum 400 mg/day)&lt;br&gt;    - 22-35 kg: Loading Dose: Three Tablets PO BID for One day (maximum 1200 mg/day). Maintenance from Day2: One tablet PO TID (maximum 800 mg/day)&lt;br&gt;    - 36-45 kg: Loading Dose: Four tablets PO BID for One day (maximum 1600 mg/day). Maintenance from Day2: Two tablets PO BID (maximum 800 mg/day)&lt;br&gt;    - 46-55 kg: Loading Dose: Five tablets PO BID for One day (maximum 2000 mg/day). Maintenance from Day2: Two Tablets qAM, Three Tablets qPM (maximum 1000 mg/day)&lt;br&gt;    - For &gt;55 kg: Can use adult dosing if age ≥16 years, if age &lt;16 years use dosing of 46-55 kg range OR&lt;br&gt;- Consider Remdesivir&lt;br&gt;  o Adult Dosing: 200 mg loading dose (IV, within 30 min), followed by 100 mg once daily for 5 to 10 days</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Remdesivir (non-formulary and non-SFDA registered) see below table “Medication Related Information”&lt;br&gt;  - Exclusion criteria evidence of multiorgan failure, need of inotropes, Creatinine clearance &lt; 30 ml/min, dialysis/hemofiltration, transaminases &gt; 5X ULN, or concomitant use of lopinavir/ritonavir</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Favipiravir (non-formulary and non-SFDA registered) (see precautions above)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Systemic Dexamethasone see below table “Medication Related Information”&lt;br&gt;  - Cardiovascular disease: Use with caution in patients with heart failure and/or hypertension; use has been associated with fluid retention, electrolyte disturbances, and hypertension. Use with caution following acute myocardial infarction; corticosteroids have been associated with myocardial rupture.</td>
<td></td>
</tr>
</tbody>
</table>
**Saudi MoH Protocol for Patients Suspected of/Confirmed with COVID-19**

Supportive care and antiviral treatment of suspected or confirmed COVID-19 infection

*(Version 3.1) August 19th, 2021*

<table>
<thead>
<tr>
<th>COVID-19 Testing</th>
<th>Category</th>
<th>Supportive Care</th>
<th>Pharmacotherapy</th>
<th>Precautions</th>
</tr>
</thead>
<tbody>
<tr>
<td>PCR confirmed cases</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Critical:
- Symptoms of the following:
  - ARDS
  - Respiratory failure requiring ventilation
  - Sepsis
  - Septic Shock
- Criteria for using tocilizumab:

### Supportive Care

- Treat symptoms
- ICU admission and management by ICU treating team
- Antibiotics and antifungals according to local antibiogram and institutional pneumonia management guidelines/pathways.

### Pharmacotherapy

- Consider starting any of the following according to clinical evaluation and treating consultant’s discretion:
  - **Remdesivir**
    - Adult Dosing: 200 mg loading dose (IV, within 30 min), followed by 100 mg once daily for 5 to 10 days
    - Pediatric dosing:
      - <40 kg: 5 mg/kg IV load, then 2.5 mg/kg q24h for 5 to 10 days
      - ≥40 kg: 200 mg IV load, then 100 mg IV q24h for 5 to 10 days
  - **Dexamethasone** (Preferable Systemic Corticosteroids):
    - Adult Dosing: 6 mg once daily oral (liquid or tablet) or intravenous preparation. Patients on chronic steroids, follow the usual recommendation of doubling steroids dose or start stress dose steroids based on clinical case basis on patients’ condition
    - Pediatric Dosing: Prednisolone/Prednisone (Oral/NG): 1 mg/kg once daily (max: 40 mg)
  - **Hydrocortisone**
    - Adult Dosing: In pregnant or breastfeeding women hydrocortisone 80 mg twice daily should be used instead of dexamethasone.
    - Pediatric Dosing: Prednisolone/Prednisone (Oral/NG): 1 mg/kg once daily (max: 40 mg)
  - **Methylprednisolone sodium succinate (IV):** 0.8 mg/kg once daily (max: 32 mg)

### Precautions

- **Diabetes:** Use corticosteroids with caution in patients with diabetes mellitus; may alter glucose production/regulation leading to hyperglycemia.
- **Gastrointestinal disease:** Use with caution in patients with GI diseases (diverticulitis, fresh intestinal anastomoses, active or latent peptic ulcer, ulcerative colitis, abscess or other pyogenic infection) due to perforation risk.
- **Myasthenia gravis:** Use with caution in patients with myasthenia gravis; exacerbation of symptoms has occurred especially during initial treatment with corticosteroids.
- **Seizure disorders:** Use corticosteroids with caution in patients with a history of seizure disorder; seizures have been reported with adrenal crisis. Labs and workup: Hemoglobin, occult blood loss, blood pressure, serum potassium, glucose, weight, and height in children; HPA axis suppression

### Anticoagulation

See below “Thromboprophylaxis”

---

**Remdesivir (non-formulary and non-SFDA registered)** (see precautions above)

**Systemic Dexamethasone:** (see precautions above)

**Baricitinib** see below table “Medication Related Information”

- Patients treated with baricitinib are at risk for developing serious infections, malignancies, and thrombosis

**Tocilizumab** see below table “Medication Related Information”
Saudi MoH Protocol for Patients Suspected of/Confirmed with COVID-19

Supportive care and antiviral treatment of suspected or confirmed COVID-19 infection

(Version 3.1) August 19th, 2021

<table>
<thead>
<tr>
<th>COVID-19 Testing*</th>
<th>Category</th>
<th>Supportive Care</th>
<th>Pharmacotherapy</th>
<th>Precautions</th>
</tr>
</thead>
<tbody>
<tr>
<td>PCR Confirmed Cases</td>
<td>1. Within 24 hours of ICU admission for MV, NIV, or HFNC oxygen</td>
<td>- &lt;40 kg: 5 mg/kg IV load, then 2.5 mg/kg q24h</td>
<td></td>
<td>- Should perform IL-6 and other inflammatory markers testing prior to start (CRP, Ferritin, D-dimer)</td>
</tr>
<tr>
<td></td>
<td>2. Patients who are exhibiting rapidly increasing oxygen needs who have a C-reactive protein level ≥75 mg/L (715 nmol/L).</td>
<td>- ≥40 kg: 200 mg IV load, then 100 mg IV q24h</td>
<td>Plus</td>
<td>- Watch for infusion reaction</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Pediatric dosing for Baricitinib</td>
<td></td>
<td>- Do not initiate if ANC is &lt;2,000/mm³, platelets are &lt;100,000/mm³, or if ALT or AST are &gt;1.5 times ULN.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- ≥ 9 years: 4 mg (oral) once daily for 5 days.</td>
<td></td>
<td>- Interrupt therapy if a patient develops a serious infection until the infection is controlled.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- 2 - 9 years: 2 mg (oral) once daily for 5 days.</td>
<td></td>
<td>Anticoagulation see below &quot;Thromboprophylaxis&quot;</td>
</tr>
</tbody>
</table>

**Systemic Corticosteroids use:**
- For all patients who require supplemental oxygen including (but not limited to) those requiring non-invasive and invasive ventilation.
- To be used up to 10 days, until discharged, or if patient becomes asymptomatic.
- Dexamethasone (Preferable Systemic Corticosteroids):
  - Adult Dosing: 6 mg once daily oral (liquid or tablet) or intravenous preparation. Patients on chronic steroids, follow the usual recommendation of doubling steroids dose or start stress dose steroids based on clinical case basis on patients' condition
  - OR
  - Prednisolone/ Prednisone
    - Adult Dosing: In pregnant or breastfeeding women, prednisolone/ Prednisone 40 mg PO twice daily should be used instead of dexamethasone.
  - OR
  - Pediatric Dosing: Prednisolone/ Prednisone (Oral/NG): 1 mg/kg once daily (max: 40 mg)
- Hydrocortisone
  - Adult Dosing: In pregnant or breastfeeding women that cannot take oral, IV hydrocortisone 80 mg twice daily should be used instead of dexamethasone.
  - Preterm infants with a corrected gestation age of <40 weeks: 0.5 mg/kg every 12 hours
- OR
- Methylprednisolone sodium succinate (IV): 0.8 mg/kg once daily (max: 32 mg)

**If rapid respiratory decompensation due to COVID-19, consider tocilizumab with dexamethasone**
- Adult Dosing:
  - Single dose of tocilizumab 8 mg/kg of actual body weight (maximum 800 mg) by IV infusion in combination with dexamethasone 6 mg daily for up to 10 days
Saudi MoH Protocol for Patients Suspected of/Confirmed with COVID-19

Supportive care and antiviral treatment of suspected or confirmed COVID-19 infection

(Version 3.1) August 19th, 2021

<table>
<thead>
<tr>
<th>COVID-19 Testing*</th>
<th>Category</th>
<th>Supportive Care</th>
<th>Pharmacotherapy</th>
<th>Precautions</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>If Tocilizumab IV is not available: use subcutaneous 162mg (a dose of 324 mg as two simultaneous 162 mg injections (&lt; 100 kg bodyweight) or 486 mg (as three simultaneous 162 mg injections) (&gt;100 kg bodyweight).</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Pediatric Dosing (&lt;18 years):</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- &lt;30 kg: 12 mg/kg repeated within 12 hours for maximum of 2 doses</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- ≥30 kg: 8 mg/kg (max: 800 mg/dose) repeated within 12 hours for maximum of 2 dose</td>
<td></td>
</tr>
</tbody>
</table>

**NOTES:**

Criteria for patients at high-risk for developing cytokine storm (1 or more of the following):

- Serum IL-6 >3x upper normal limit
- Ferritin >300 ug/L (or surrogate) with doubling within 24 hours
- Ferritin >600 ug/L at presentation and LDH >250
- Elevated D-dimer (>1 mcg/mL)

Tocilizumab is registered medications in Saudi Arabia and available in MoH formulary for other indications but have not shown proven efficacy in many randomized clinical trials as of yet and their use in this setting is considered off-label. Remdesivir favipiravir, casirivimab plus imdevimab, and sotrovimab are not currently registered by SFDA.

Pregnancy and Lactation: Management of infection with SARS-COV2 in pregnancy is mainly based on supportive care. Consideration of antiviral therapy should be based on patient condition, safety profile and preference of the patient and treating team. Refer to the MoH COVID-19 guidance in pregnancy.

**Thromboprophylaxis:**

**Recommendations**

- All admitted patients should be evaluated upon admission, and daily thereafter for both thrombotic and bleeding risk.
- Laboratory evaluation and monitoring: Baseline CBC, fibrinogen, PT, aPTT, D-dimer on admission, and serially.
- Baseline or surveillance imaging are not recommended in the absence of clinical symptoms of VTE
- Patients on chronic VTE prophylaxis should continue as planned before.
- Warfarin, DOAC and antiplatelet medications are not recommended to be used as prophylaxis
- For patients whom anticoagulant therapy is contraindicated, mechanical thromboprophylaxis, preferably with intermittent pneumatic compression devices, should be utilized, although there is limited evidence of efficacy in hospitalized medically ill patients
- Thromboprophylaxis should continue until the time of discharge at least. Continuation of anticoagulation is subject to assessment of VTE risk by the treating medical team.
- Heparin induced thrombocytopenia (HIT)
- Platelets below 50 x 10^9/L
- Unexplained bleeding
- Inherited bleeding disorder (Hemophilia, thrombasthenia)
- Inherited red blood disorder (sickle cell disease)
- Previously on anticoagulation therapy
- Radiological evidence of thrombosis

**Adults:**

- Therapeutic doses should not be offered because of the risk of bleeding
- Thromboprophylaxis with low molecular weight heparin (LMWH) should be considered in ALL patients (including non-critically ill) who require hospital admission for COVID-19 infection, in the absence of any contraindications (active bleeding and platelet count less than 25 x 10^9/L; monitoring is advised in severe renal impairment; abnormal PT or aPTT is not a contraindication)
- Enoxaparin prophylaxis doses:
  - 40 mg subcutaneously once daily
Supportive care and antiviral treatment of suspected or confirmed COVID-19 infection

(Version 3.1) August 19th, 2021

<table>
<thead>
<tr>
<th>COVID-19 Testing*</th>
<th>Category</th>
<th>Supportive Care</th>
<th>Pharmacotherapy</th>
<th>Precautions</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Obesity: BMI &gt; 40 kg/m²: 40 mg subcutaneously every 12 hours</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pregnancy: 40 mg subcutaneously once daily</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Renal impairment:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- CrCl &gt; 30 mL/minute: no adjustments required</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- CrCl &lt; 30 mL/minute: 30 mg subcutaneously once daily</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hemodialysis and CRRT: Avoid use if possible but if used, anti-Xa levels should be frequently monitored, as accumulation may occur with repeated doses.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Patients with Heparin-induced thrombocytopenia (HIT), please follow MoH HIT protocol for alternative anticoagulation.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Pediatrics:**
- Enoxaparin prophylaxis doses:
  - Infants 1-<2 months: 0.75 mg/kg/dose subcutaneously every 12 hours
  - Infants ≥ 2 months, children, and adolescents: 0.5 mg/kg/dose subcutaneously every 12 hours
- Renal impairment: No pediatric specific recommendations (use with caution and monitor patient closely).
- Dialysis: not approved but if used, dosages should be reduced and anti-Xa levels frequently monitored, as accumulation may occur with repeated doses.
- Hemodialysis: Not dialyzable and supplemental dose is not necessary.

**Enoxaparin monitoring**
- Routine anti-Xa levels are not recommended.
- If an anti-Xa level is deemed necessary, it should be drawn 4-6 hours after enoxaparin administration with an anti-Xa goal of 0.2-0.4 units/mL for prophylaxis and 0.5-1 Units/mL for therapeutic dose.
- Consider re-checking anti-Xa if the patient experiences active bleeding or has evidence of renal dysfunction while on enoxaparin therapy.

**Contraindications to Anticoagulation (Bleeding Risk Factors)**
- Intracranial hemorrhage, Brain ischemia/acute stroke, ongoing and uncontrolled bleeding /hematoma, congenital bleeding disorder
- Uncorrected coagulopathy: INR >1.5, APTT >44 seconds, fibrinogen <100 g/dL, or platelet <50,000/microliter

**Consider Avoiding Anticoagulation**
- Intracranial mass, Recent lumbar puncture / Epidural (<24 hours ago), The patient is likely to require an invasive procedure within 24 hours of starting enoxaparin, Neurosurgical procedure, Pelvic fracture within past 48 hours, Recent aspirin or antiplatelet use (<5-7 days ago), Uncontrolled hypertension

**Multisystem Inflammatory Syndrome in Children (MIS-C)**

**Criteria for Management:**
- Patient aged ≤ 21 years presenting with fever (>38.0°C for ≥24 hours, or report of subjective fever lasting ≥24 hours), laboratory evidence of inflammation (including, but not limited to, one or more of the following: an elevated CRP, ESR, fibrinogen, procalcitonin, D-dimer, ferritin, LDH, or IL-6; elevated neutrophils; reduced lymphocytes; and low albumin), and evidence of clinically severe illness requiring hospitalization, with multisystem (≥2) organ involvement (cardiac, renal, respiratory, hematologic, gastrointestinal, dermatologic or neurological)
- No alternative plausible diagnoses
- Positive for current or recent SARS-CoV-2 infection by RT-PCR, serology, or antigen test; or COVID-19 exposure within the 4 weeks prior to the onset of symptoms

**Management:**
There are no established therapies for COVID-19-associated CSS or MIS-C. These medications are to be used only with guidance from Rheumatology, Cardiology and Infectious Diseases. Patients who are being evaluated for immunomodulatory therapy should also be considered for antiviral therapy if they are not already receiving it.
- Supportive Care: Children with moderate to severe signs and symptoms should be admitted to the hospital. Admission to a pediatric intensive care unit is appropriate for children with hemodynamic instability (shock, arrhythmia), significant respiratory compromise, or other potentially life-threatening complications
- Thromboprophylaxis (see above section)
Saudi MoH Protocol for Patients Suspected of/Confirmed with COVID-19
Supportive care and antiviral treatment of suspected or confirmed COVID-19 infection

(Version 3.1) August 19th, 2021

<table>
<thead>
<tr>
<th>COVID-19 Testing*</th>
<th>Category</th>
<th>Supportive Care</th>
<th>Pharmacotherapy</th>
<th>Precautions</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Antiviral therapy (see above based of patient category) - Immunomodulator Dosing and Monitoring</td>
<td>Immunomodulator</td>
<td>Dosing</td>
<td>Safety monitoring</td>
<td></td>
</tr>
<tr>
<td>IVIG with methylprednisolone see below table</td>
<td>- IVIG 2 g/kg + methylprednisolone at 0.8 to 1 mg/kg every 12 hours (maximum of 30 mg for 12 hours) for 5 days - IVIG 2 g/kg + methylprednisolone bolus of 15 to 30 mg/kg/d for 3 days</td>
<td>- Assess cardiac function and fluid status prior to giving to avoid fluid overload - Baseline renal function tests, urine output, IgG level, CBC - Monitor clinically for signs of hemolysis after first dose - Potential adverse reactions: anaphylaxis, - Infusion reaction, hemolysis, transaminits, aseptic meningitis - Pulmonary adverse reactions; blood pressure (prior to, during, and following infusion); clinical response. - For patients at high risk of hemolysis (dose ≥2 g/kg, given as a single dose or divided over several days, and non-O blood type): Hemoglobin or hematocrit prior to and 3 to 96 hours post-infusion and again at 7 to 10 days post-infusion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>“Medication Related Information” MIS-C with or without features of Kawasaki disease or signs of myocardial dysfunction</td>
<td>Glucocorticoids</td>
<td>- 1-2 mg/kg/day divided BID (prednisone, prednisolone, methylprednisolone) - 5 mg/m2 daily (dexamethasone)</td>
<td>(see precautions above)</td>
<td></td>
</tr>
<tr>
<td>OR Severe or critical COVID-19 with evidence of CSS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations:

Footnotes:
*Testing for SARS-COV2 virus shall be performed in accordance with published case definition by Saudi CDC guidelines.

High risk patients have one or more: 1. Elderly (age > 65 years), 2. With underlying end organ dysfunction, 3. Diabetes, 4. History of cardiovascular disease, 5. History of pulmonary disease, 6. Immunocompromised, and/or 7. Pregnancy

Medication Related Information

<table>
<thead>
<tr>
<th>Medication</th>
<th>Contraindication</th>
<th>Major Drug Interactions</th>
<th>Required dose adjustment</th>
<th>Pregnancy and Lactation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paracetamol (acetaminophen)</td>
<td>- Hypersensitivity to acetaminophen or any component of the formulation - Severe hepatic impairment or active liver disease</td>
<td>- Acetaminophen may increase the levels/effects of: Busulfan; Dasatinib; Imatinib; Local Anesthetics; Mipomersen; Phenylephrine (Systemic); Prilocaine; Sodium Nitrite; SORAfelin; Vitamin K Antagonists - The levels/effects of Acetaminophen may be increased by: Alcohol (Ethyl); Dasone (Topical); Dasatinib; Flucloxacinil; Isoniazid; Metyrapone; Nitric Oxide; Probencid; SORAfelin</td>
<td>- Requires dose adjustment with patient with hepatic impairment</td>
<td>- Oral paracetamol is considered safe in normal therapeutic doses for short-term use as a minor analgesic/antipyretic in pregnancy. - Consider Administering IV paracetamol to a pregnant woman</td>
</tr>
</tbody>
</table>
### Medication Related Information

<table>
<thead>
<tr>
<th>Medication</th>
<th>Contraindication</th>
<th>Major Drug Interactions</th>
<th>Required dose adjustment</th>
<th>Pregnancy and Lactation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Remdesivir</td>
<td>Safety and efficacy not established</td>
<td>Avoid Concomitant Use: There are no known interactions where it is recommended to avoid concomitant use.</td>
<td>No dose adjustment studied</td>
<td>Only if clearly needed. Carefully assess maternal benefit and fetal risk before administering IV paracetamol during labor and delivery.</td>
</tr>
<tr>
<td>Favipiravir</td>
<td>Hemaotopoietic tissues such as decreased RBC production, and increases in liver function parameters Testis toxicity was also noted – Teratogenic</td>
<td>Acyclovir, Adefovir dipivoxil, Aflatoxin, Allopurinol, Almotriptan, Alprostadil, Ambriensian, Aminohippuric acid, Aminophenazon, Amiodarone, Amytripryline, Amodiaquine; Anastrozole, Antipyrine, Aplaliatam, Apixaban; Astrovastatin, Avatrombopag, Avibactam, Axelastine, Baricitinib, Belinostat, Benzyl alcohol, Benzylpenicillin, Betrixaban, Bisoprolol, Boutinib, Binxutimab vedotin, Britiginib, Bunetarnide, Buprenorphine, Cazabasatal, Canagliflozin, Captopril, Cefacol, Cefazolin, Cefdinir, Cefotiam, Ceftibuten, Ceftizoxime, Ceflozip, Cephalexin, Cerrinitb, Cervastatin, Chloroquine, Cholic Acid, Cidofovir, Cimetidine, Cisapride, Citrulline, Clobazam, Clomifene, Cobimetinib, Colchicine, Conjugaed estrogen, Conaprisib, Crizotinib, Cyclophosphamide, Cyclosporine, Dabigatran etexilate, Zafirlukast, Zaliczakine, Zidovudine, Zopiclone.</td>
<td>No dose adjustment studied</td>
<td>Contraindicated.</td>
</tr>
<tr>
<td>Tocilizumab</td>
<td>Known hypersensitivity to tocilizumab or any component of the formulation Active infections</td>
<td>Avoid Concomitant Use: Anti-TNF Agents; BCG (Intravesical); Belimubam; Biologic Disease-Modifying Antirheumatic Drugs (DMARDs); Cladribine; Natalizumab; Pimecrolimus; Tacrolimus (Topical); Vaccines (Live)</td>
<td>Requires dose adjustment with patient with hepatotoxicity</td>
<td>See MoH online formulary.</td>
</tr>
<tr>
<td>Baricitinib</td>
<td>Hypersensitivity to Baricitinib or any component of formuation</td>
<td>Need therapy modification and monitoring; 5-Aminosalicylic Acid Derivatives, Chloramphenicol (Ophthalmic); CloZAPine Deferiprone, Denosumam, Echinacea, Fingolimod, Leflunomide; Natalizumam; Nitisinone; Nivolumam; Pidotimod; Pretomanid, Probenecid, Promazine, Rofumilast, Tigulucel-T, and Tertomotide. Avoid combination: Vaccines (Live), Talimogene Laherparepvec, Tacrolimus (Topical), Belimubam, Biologic Disease-Modifying Antirheumatic Drugs, Cladribine, Cisplatin, Dipyrox, Natalizumab, Pimecrolimus.</td>
<td>Requires dose adjustment with patient with renal and liver impairment</td>
<td>Not recommended in breastfeeding. Information related to pregnancy is limited</td>
</tr>
<tr>
<td>Systemic Dexamethasone</td>
<td>Concomitant use of more than a single dose of dexamethasone with rilpivirine Hyper-sensitivity to dexamethasone or any component of the product - Systemic fungal infection</td>
<td>Avoid concomitant use of Dex/MEHTaHone (Systemic) with any of the following: Aldesleukin; BCG (Intravesical); Cladribine; Convaptic; Desmopresin; Fudic Acid (Systemic); Idelalisib; Indium 111 Capromab Penetide; Lapatinib; Lasmiditan; Macimoren; Mifamurtide; MFEPRISTone; Natalizumab; Pimecrolimus; Rilpivirine; Simprevir; Tacrolimus (Topical); Upadacitinib</td>
<td>Use cautiously in the elderly at the lowest possible dose</td>
<td>See MoH online formulary.</td>
</tr>
<tr>
<td>Inhaled budesonide (Pulmicort®)</td>
<td>Hyper-sensitivity to budesonide - Allergic cross-reactivity for corticosteroids is limited - Patients with cirrhosis</td>
<td>Diminish the effect of: Aldesleukin and Consyntropin - Enhance the effect/toxicity of: Desmopresin and Loxapine - Increase the serum concentration of Budesonide: CYP3A4 Inhibitors - Diminish the effect of Budesonide: Tobacco</td>
<td>Use cautiously in hepatic impairment</td>
<td>Present in breast milk.</td>
</tr>
</tbody>
</table>
Saudi MoH Protocol for Patients Suspected of/Confirmed with COVID-19

Supportive care and antiviral treatment of suspected or confirmed COVID-19 infection

(Version 3.1) August 19th, 2021

Medication Related Information

<table>
<thead>
<tr>
<th>Medication</th>
<th>Contraindication</th>
<th>Major Drug Interactions</th>
<th>Required dose adjustment</th>
<th>Pregnancy and Lactation</th>
</tr>
</thead>
<tbody>
<tr>
<td>IVIG</td>
<td>Hypersensitivity to IVIG or any component of the formula</td>
<td>MMR, varicella vaccines</td>
<td>Use cautiously with Renal impairment due to risk of immune globulin-induced renal dysfunction; the rate of infusion and concentration of solution should be minimized. Discontinue if renal function deteriorates.</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Documentation of allergic cross-reactivity</td>
<td></td>
<td></td>
<td>-</td>
</tr>
<tr>
<td>Enoxaparin</td>
<td>Active major bleeding</td>
<td></td>
<td></td>
<td>- Low molecular weight heparin (LMWH) does not cross the placenta; increased risks of fetal bleeding or teratogenic effects have not been reported (Bates 2012).</td>
</tr>
<tr>
<td></td>
<td>History of immune-mediated heparin-induced thrombocytopenia within the past 100 days or in presence of circulating antibodies</td>
<td></td>
<td></td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Hypersensitivity to benzyl alcohol (present in multi-dose formulation)</td>
<td></td>
<td></td>
<td>-</td>
</tr>
<tr>
<td>Castrivimab plus imdevimab</td>
<td>Hypersensitivity to Castrivimab or imdevimab</td>
<td>COVID-19 Vaccine: effect may be diminished</td>
<td>No dose adjustment studied</td>
<td>Not known</td>
</tr>
<tr>
<td>Sotrovimab</td>
<td>Hypersensitivity to Sotrovimab</td>
<td>COVID-19 Vaccine: effect may be diminished</td>
<td>No dose adjustment studied</td>
<td>Not studied</td>
</tr>
</tbody>
</table>

Drug Administration in patients with Swallowing Difficulties

<table>
<thead>
<tr>
<th>Drug</th>
<th>Formulation</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Favipiravir</td>
<td>Tablets</td>
<td>Tablets can be crushed and mixed with liquid.</td>
</tr>
<tr>
<td>Baricitinib</td>
<td>Tablet</td>
<td>Tablets can be mixed with room temperature water.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Administration via</th>
<th>Dispersion Volume</th>
<th>Container Rinse Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral dispersion</td>
<td>10 mL</td>
<td>10 mL</td>
</tr>
<tr>
<td>Gastrostomy tube</td>
<td>15 mL</td>
<td>15 mL</td>
</tr>
<tr>
<td>Nasogastric tube</td>
<td>30 mL</td>
<td>15 mL</td>
</tr>
</tbody>
</table>

References:
Saudi MoH Protocol for Patients Suspected of/Confirmed with COVID-19

Supportive care and antiviral treatment of suspected or confirmed COVID-19 infection

(Version 3.1) August 19th, 2021

8. NHS Thromboprophylaxis and anticoagulation in COVID-19 infection. Imperial College Healthcare V 0.1.08.04.2020 Covid Treatment Group
18. Micromedx last access May 20, 2020
32. Food and Drug Administration. FACT SHEET FOR HEALTHCARE PROVIDERS EMERGENCY USE AUTHORIZATION (EUA) OF BARICITINIB. https://www.fda.gov/media/136189/download
33. National Institute of Allergy and Infectious Diseases. Adaptive COVID-19 Treatment: Trial 2 (ACTT-2). ClinicalTrials.gov Identifier: NCT04401579
Saudi MoH Protocol for Patients Suspected of/Confirmed with COVID-19

Supportive care and antiviral treatment of suspected or confirmed COVID-19 infection

(Version 3.1) August 19th, 2021


Summary of Protocol changes

- Addition of Tocilizumab criteria for Interruption and no initiation under critical confirmed PCR cases precaution
- Addition of Anti-SARS-CoV-2 Monoclonal antibodies under:
  - PCR confirmed mild to moderate cases for non-hospitalized patients
  - Medication related information table
  - Criteria for using Monoclonal Antibodies